BioNTech Valuation
Is BNTX N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BNTX N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BNTX N's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BNTX N's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BNTX N?
Key metric: As BNTX N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BNTX N's PS Ratio? | |
|---|---|
| PS Ratio | 8.6x |
| Sales | €3.04b |
| Market Cap | €26.05b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | -30.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BNTX N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.8x | ||
MRNA Moderna | 3.1x | 6.8% | US$15.8b |
BIIB Biogen | 2.4x | 1.3% | US$23.0b |
603392 Beijing Wantai Biological Pharmacy Enterprise | 36.9x | 60.9% | CN¥92.6b |
A068270 Celltrion | 12.7x | 25.4% | ₩35.8t |
BNTX N BioNTech | 8.6x | 3.4% | Mex$27.1b |
Price-To-Sales vs Peers: BNTX N is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (13.8x).
Price to Sales Ratio vs Industry
How does BNTX N's PS Ratio compare vs other companies in the Global Biotechs Industry?
| 278 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 278 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: BNTX N is good value based on its Price-To-Sales Ratio (8.6x) compared to the Global Biotechs industry average (9x).
Price to Sales Ratio vs Fair Ratio
What is BNTX N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BNTX N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$2,116.00 | Mex$2,745.75 +29.8% | 9.5% | Mex$3,445.12 | Mex$2,427.65 | n/a | 18 |
| Nov ’25 | Mex$2,250.00 | Mex$2,616.56 +16.3% | 17.1% | Mex$3,460.54 | Mex$1,808.88 | n/a | 18 |
| Oct ’25 | Mex$2,349.99 | Mex$2,404.75 +2.3% | 19.6% | Mex$3,316.58 | Mex$1,648.59 | n/a | 18 |
| Sep ’25 | Mex$1,755.59 | Mex$2,186.34 +24.5% | 20.4% | Mex$3,428.71 | Mex$1,704.33 | n/a | 18 |
| Aug ’25 | Mex$1,612.00 | Mex$2,095.27 +30.0% | 20.3% | Mex$3,211.76 | Mex$1,692.04 | n/a | 18 |
| Jul ’25 | n/a | Mex$2,029.53 0% | 20.2% | Mex$3,127.99 | Mex$1,637.31 | n/a | 18 |
| Jun ’25 | n/a | Mex$1,897.73 0% | 20.4% | Mex$2,921.12 | Mex$1,532.47 | n/a | 18 |
| May ’25 | n/a | Mex$1,948.12 0% | 20.7% | Mex$2,878.11 | Mex$1,521.37 | n/a | 18 |
| Apr ’25 | n/a | Mex$1,943.30 0% | 23.6% | Mex$3,097.38 | Mex$1,488.58 | n/a | 18 |
| Mar ’25 | Mex$1,598.00 | Mex$2,157.75 +35.0% | 22.5% | Mex$3,206.78 | Mex$1,687.21 | n/a | 17 |
| Feb ’25 | Mex$1,599.00 | Mex$2,183.28 +36.5% | 22.4% | Mex$3,221.25 | Mex$1,694.82 | n/a | 16 |
| Jan ’25 | Mex$1,779.00 | Mex$2,255.38 +26.8% | 21.0% | Mex$3,161.27 | Mex$1,708.08 | n/a | 16 |
| Dec ’24 | Mex$1,679.00 | Mex$2,316.17 +37.9% | 23.0% | Mex$3,421.07 | Mex$1,704.72 | n/a | 17 |
| Nov ’24 | Mex$1,700.00 | Mex$2,482.83 +46.0% | 23.1% | Mex$3,443.12 | Mex$1,813.59 | Mex$2,250.00 | 17 |
| Oct ’24 | n/a | Mex$2,547.89 0% | 22.9% | Mex$3,430.18 | Mex$1,729.28 | Mex$2,349.99 | 16 |
| Sep ’24 | Mex$2,090.00 | Mex$2,642.56 +26.4% | 26.1% | Mex$4,221.20 | Mex$1,681.27 | Mex$1,755.59 | 17 |
| Aug ’24 | Mex$1,776.00 | Mex$2,706.51 +52.4% | 24.7% | Mex$4,196.10 | Mex$1,819.27 | Mex$1,612.00 | 17 |
| Jul ’24 | Mex$1,846.50 | Mex$2,833.95 +53.5% | 23.1% | Mex$4,257.54 | Mex$1,845.91 | n/a | 16 |
| Jun ’24 | Mex$1,842.00 | Mex$2,828.45 +53.6% | 23.4% | Mex$4,309.50 | Mex$1,868.43 | n/a | 17 |
| May ’24 | n/a | Mex$3,196.27 0% | 23.7% | Mex$4,720.76 | Mex$2,294.86 | n/a | 17 |
| Apr ’24 | n/a | Mex$3,315.15 0% | 22.2% | Mex$4,691.92 | Mex$2,357.14 | n/a | 16 |
| Mar ’24 | Mex$2,482.00 | Mex$3,749.96 +51.1% | 23.4% | Mex$5,410.03 | Mex$2,570.63 | Mex$1,598.00 | 15 |
| Feb ’24 | Mex$2,630.00 | Mex$3,946.72 +50.1% | 23.5% | Mex$5,698.09 | Mex$2,716.67 | Mex$1,599.00 | 15 |
| Jan ’24 | Mex$3,005.80 | Mex$4,224.52 +40.5% | 23.2% | Mex$6,498.75 | Mex$3,016.98 | Mex$1,779.00 | 15 |
| Dec ’23 | Mex$3,235.00 | Mex$4,091.06 +26.5% | 22.4% | Mex$6,198.42 | Mex$2,892.27 | Mex$1,679.00 | 16 |
| Nov ’23 | Mex$2,765.00 | Mex$4,175.23 +51.0% | 24.6% | Mex$6,259.26 | Mex$2,628.15 | Mex$1,700.00 | 16 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
ICON
US$17.7b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a